FREMONT, Calif., Oct. 19, 2016 -- Lam Research Corporation (NASDAQ:LRCX) today announced that it will hold the company’s analyst and investor meeting on Friday, November 18, 2016, from 9:00 a.m. to 12:30 p.m. Eastern Time at the Mandarin Oriental, New York. The meeting was previously scheduled for Wednesday, November 16, 2016 at the Fremont Marriott Silicon Valley.
The meeting will serve as a general update for investors and analysts on Lam’s strategy and operations. A live webcast and replay of the meeting will be available to the public on the Investors section of the company's website.
If you are an institutional investor or financial analyst interested in attending the event in person, please direct your questions to [email protected].
About Lam Research:
Lam Research Corp. (Nasdaq:LRCX) is a trusted global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's broad portfolio of market-leading deposition, etch, and clean solutions helps customers achieve success on the wafer by enabling device features that are 1,000 times smaller than a grain of sand, resulting in smaller, faster, more powerful, and more power-efficient chips. Through collaboration, continuous innovation, and delivering on commitments, Lam is transforming atomic-scale engineering and enabling its customers to shape the future of technology. Based in Fremont, Calif., Lam Research is a Nasdaq-100 Index® and S&P 500® company whose common stock trades on the Nasdaq Global Select MarketSM under the symbol LRCX. For more information, please visit http://www.lamresearch.com. (LRCX-F)
Lam Research Corporation Contact: Satya Kumar Investor Relations Phone: 510-572-1615 e-mail: [email protected]


FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Italy Fines Apple €98.6 Million Over App Store Dominance
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 



